Related Experiment Video
Updated: Aug 2, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
[Olaparib Could Be Re-Administered after Chemotherapy]
Risa Terasawa1, Yuko Takashima, Aoko Hirata
1Dept. of Breast and Endocrine Surgery, Hirakata City Hospital.
Abstract:
Olaparib, a PARP inhibitor, was approved in 2018 for BRCA1/2 gene mutation and HER2-negative inoperable or recurrent breast cancer with previous chemotherapy. Olaparib is an important drug with minor adverse events compared to chemotherapeutic drugs. In addition, it is expected to exert a high therapeutic effect on breast cancer with BRCA mutations due to its characteristics. We report a case of BRCA2-mutated breast cancer in a patient in whom olaparib was initiated. The patient complained of strong nausea; however, the treatment could be continued by reducing the dose of olaparib to 400 mg and using multiple drugs such as antiemetics and anxiolytics in advance.
Related Concept Videos
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Restarting Stalled Replication Forks

